Sotorasib
- Generic Name
- Sotorasib
- Brand Names
- Lumakras, Lumykras
- Drug Type
- Small Molecule
- Chemical Formula
- C30H30F2N6O3
- CAS Number
- 2252403-56-6
- Unique Ingredient Identifier
- 2B2VM6UC8G
- Background
Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s. It is the first expe...
- Indication
Sotorasib is indicated in the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received at least one prior systemic therapy.
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
A Study of Sotorasib in People with Non-Small Cell Lung Cancer
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06582771
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 80
- Registration Number
- NCT06532149
- Locations
- 🇮🇹
Fondazione Policlinico Gemelli IRCCS, Rome, Italy
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 320
- Registration Number
- NCT06497556
- Locations
- 🇺🇸
Banner Health MD Anderson AZ, Gilbert, Arizona, United States
🇺🇸Cancer Specialists of North Florida, Jacksonville, Florida, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 500
- Registration Number
- NCT06333951
- Locations
- 🇯🇵
Aichi Cancer Center, Nagoya-shi, Aichi, Japan
🇺🇸Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 160
- Registration Number
- NCT06333678
- Locations
- 🇺🇸
Lehigh Valley Health Network (Dara Collection Only), Allentown, Pennsylvania, United States
🇺🇸University of Miami (Data Collection Only), Miami, Florida, United States
🇺🇸University of Michigan (Data Collection Only), Ann Arbor, Michigan, United States
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 450
- Registration Number
- NCT06252649
- Locations
- 🇺🇸
Orchard Healthcare Research Inc, Skokie, Illinois, United States
🇺🇸Pikeville Medical Center, Pikeville, Kentucky, United States
🇺🇸Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT06249282
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Registration Number
- NCT06068153
- Locations
- 🇪🇸
Hospital Universitario Y Politécnico La Fe, Valencia, Spain
🇦🇹Medical University of Innsbruck / UK für Innere Medizin V, Innsbruck, Austria
🇨ðŸ‡Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
A Clinical Trial to Evaluate Bioavailability and Effect of Food for Sotorasib in Healthy Participants
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Amgen
- Registration Number
- NCT06061523
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Conditions
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 750
- Registration Number
- NCT05920356
- Locations
- 🇧🇷
Associação Beneficente de Canoas, Canoas, Rio Grande Do Sul, Brazil
🇨🇳Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳Chi Mei Hospital, Liouying, Tainan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.